Evidence map›Paper›PMID 34611235›Full record

ArticleScientific reports2021

Second primary malignancy among malignant solid tumor survivors aged 85 years and older.

Zhijia Zhang, Fei Liu, Yanlin Qu, Liqian Qiu, Liqun Zhang, Qiao Yang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zhijia ZhangDepartment of Clinical Laboratory, The Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Fei LiuDepartment of Clinical Laboratory, The Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Yanlin QuDepartment of Respiratory Medicine, The 941st Hospital of the PLA Joint Logistic Support Force, Xining, 810007, China.
Liqian QiuDepartment of Ultrasound, The 941st Hospital of the PLA Joint Logistic Support Force, Xining, 810007, China.
Liqun ZhangDepartment of Clinical Laboratory, The Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China. 1434103777@qq.com.
Qiao YangDepartment of Ultrasound, The 941st Hospital of the PLA Joint Logistic Support Force, Xining, 810007, China. joeyse7en@aliyun.com.
81th Hospital of PLA · CNSecond Affiliated Hospital of Chongqing Medical University · CNChongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cancer burden in the oldest old has increased rapidly. This study aimed to investigate the epidemiology of second primary malignancy (SPM) in malignant solid tumor survivors aged 85 years and older utilizing the Surveillance, Epidemiology, and End Results (SEER) database. A total of 128,466 malignant solid tumor patients had been identified between 2000 and 2011, including 6774 patients who developed a SPM. The overall crude incidence of developing a SPM was 5.3%. Considering death as a competing event, the 3, 5, and 10-year cumulative incidence was 1.9%, 3.2%, and 5.4%, respectively. Relative younger age, male gender, surgery history, local stage and first primary malignancy (FPM) site located in the urinary system were related to higher cumulative incidence. A median time interval of 24.0 months was found between diagnosis of FPM and SPM. The most common SPM site was digestive system, whereas the least common was oral cavity and pharynx. The median overall survival (OS) was 49.0 months, and the median survival after SPM was 13.0 months. Relative older age, male gender and black race were associated with worse OS and survival after SPM, as well as higher hazard ratios of death. In conclusions, this study performed a comprehensive analysis of SPM among malignant solid tumor survivors aged 85 years and older. Additional studies are needed to characterize the specific cancer type of interest.

Indexed as

Aged, 80 and overAge FactorsCancer SurvivorsDisease SusceptibilityFemaleHumansIncidenceMaleNeoplasms, Second PrimaryPrognosisPublic Health SurveillanceRisk AssessmentRisk Factors

Identifiers

PMID34611235
PMCPMC8492691
OpenAlexW3204315090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.